Danforth Health Acquires Ambit, Expanding its Integrated Capabilities Across the Rare and Specialty Disease Product Lifecycle
WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) — Danforth Health, Inc. today announced the acquisition of Ambit RD, Inc., a technology-enabled solutions company specializing in commercial strategy, advanced analytics, and patient identification for rare and specialty biopharma companies.
With the addition of Ambit, Danforth takes another step toward becoming the complete backbone for life science companies across the product journey — now with more tools for driving commercial performance at and beyond launch. Rob Sederman and Ned Kitfield will continue in their roles as Chief Executive Officer and Chief Commercial Officer of the rapidly growing business.
Founded to help biopharma companies overcome the unique challenges of rare and specialty disease markets, Ambit brings a powerful combination of data-driven consulting, proprietary technology, and deep commercial expertise to identify patients and activate healthcare providers. The company’s three core solution areas — Strategic Services, Analytics & Data Services, and Patient ID Services — are supported by a growing product portfolio that leverages AI for digital transformation and for broadening clinical research services to accelerate clinical trial recruitment.
“What makes this acquisition right for Danforth is not just what Ambit brings, but how naturally it fits. They add specialized capabilities at the stage where execution can make or break a product’s success, and with a depth of expertise in rare and specialty disease that amplifies our own,” said Chris Connors, Chief Executive Officer of Danforth Health. “Our differentiation has always been connecting business, science, and commercial in a way no one else does. Ambit makes that story more powerful and our platform more complete.”
“Joining Danforth gives us something rare: a platform where commercial strategy, data, and technology sit alongside the full spectrum of business and clinical capabilities,” said Kitfield. “For our clients, that means a more connected, more powerful partner at every stage of the product journey.”
Danforth’s existing commercialization platform spans go-to-market and brand strategy, market access, launch planning, omnichannel execution, and market research. Ambit fills meaningful gaps and deepens existing strengths — adding dedicated medical planning, a data and analytics layer that sharpens commercial decision-making, and AI-powered technology that moves clients from insight to activation much faster. Together, these additions make Danforth a uniquely comprehensive commercialization partner in life sciences.
Ambit is the latest in a series of strategic acquisitions, supported by growth investment from Avesi Partners, that have expanded Danforth’s integrated capabilities across the product lifecycle. Previous acquisitions include Asymmetry Group and PharmaDirections (2025), VPMR, Advyzom, and Benchworks (2024), Elite BioPharma Consulting (2023), and Argot Partners (2022). By uniting the capabilities of its affiliates, Danforth provides cohesive strategies, accelerates execution, and delivers streamlined support across business, clinical, and commercial functions.
Clearsight Advisors, Inc. served as the exclusive financial advisor to Ambit.
About Ambit
Ambit is a rapidly growing, tech-enabled solutions company that helps biopharma clients overcome challenges in rare and specialty disease markets. Through a combination of best-in-class talent, cutting-edge technology, and advanced data analytics, Ambit delivers services and products that move clients from analysis to insight to activation. For additional information, visit www.ambitinc.com.
About Danforth Health
Danforth Health empowers life science innovation as a single, connected partner for strategy and execution across business operations, asset development, and commercialization. Acting as a flexible, embedded extension of client teams, Danforth helps companies reduce risk, advance with efficiency, and direct investment toward the decisions that ultimately drive patient impact. Headquartered in Waltham, Massachusetts, the company has partnered with more than 1,800 life science companies worldwide. Additional information is available at www.danforthhealth.com.
CONTACT: Contact: Felicia Krupps Danforth Health fkrupps@danforthadvisors.com
